Results 61 to 70 of about 684,930 (357)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution

Cancer Management and Research, 2018
Shu-Wei Chen,1–3,* Quan Zhang,1–3,* Zhu-Ming Guo,1–3 Wen-Kuan Chen,1–3 Wei-Wei Liu,1–3 Yan-Feng Chen,1–3 Qiu-Li Li,1–3 Xue-Kui Liu,1–3 Hao Li,1–3 Dian Ou-Yang,1–3 Wei-Chao Chen,1–3 Xiao ...
Chen SW, Zhang Q, Guo ZM, Chen WK, Liu WW, Chen YF, Li QL, Liu XK, Li H, Ou-Yang D, Chen WC, Fu XY, Wang XD, Yang AK, Bei JX, Song M   +15 more
doaj  

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

A multimodal neuroimaging classifier for alcohol dependence [PDF]

, 2020
With progress in magnetic resonance imaging technology and a broader dissemination of state-of-the-art imaging facilities, the acquisition of multiple neuroimaging modalities is becoming increasingly feasible.
Garbusow, Maria, Guggenmos, Matthias, Heinz, Andreas, Lett, Tristram, Schmack, Katharina, Sebold, Miriam, Sekutowicz, Maria, Smolka, Michael N., Sommer, Christian, Sterzer, Philipp, Veer, Ilya M., Walter, Henrik, Wittchen, Hans-Ulrich, Zimmermann, Ulrich S.   +13 more
core   +1 more source

Decrypting cancer's spatial code: from single cells to tissue niches

Molecular Oncology, EarlyView.
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik, Shi Pan, Eloise Withnell, Hou Wang Lam, Maria Secrier   +4 more
wiley   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Stage T4B head and neck cancer survival outcome comparisons based on treatment modality: is surgery a viable treatment option? [PDF]

, 2016
IMPORTANCE: Advanced stage head and neck cancers are often deemed unresectable due to the aggressive nature of the cancer. In evaluating survival patterns of patients with stage IVb tumors, it is valuable to determine whether patients who undergo ...
Kidwai, Neiha
core   +1 more source

Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis [PDF]

, 2018
Background. There is little information about quality of life (QoL) for patients with end-stage kidney disease (ESKD) choosing conservative kidney management (CKM).
Barendse, Brown, Chandna, Da Silva-Gane, Davies, De Biase, Devins, Helvik, Hussain, Iyasere, Jakobsson, Jassal, Johansen, Kamar, Mahoney, Morton, Murphy, Murtagh, O'Connor, Okamoto, Rockwood, Roshanravan, Seow, Sexton, Shum, Verberne, Zigmond   +26 more
core   +4 more sources

Warts treatment modalities

Baghdad Medical Journal Of Students, 2020
Warts are common problem in the communities and caused by many types of human papilloma virus. There are many modalities of treatment in which none was shown to be perfect and only few were based on high-level clinical trials. Treatment should be individualized in practice depending on many factors like immunity status, age, number and sites of the ...
openaire   +2 more sources